替尔泊肽降低血尿酸及其与减重关联:SURMOUNT-1 事后分析
SURMOUNT-1 随机安慰剂对照试验的事后分析纳入 2539 例肥胖或超重成人,比较替尔泊肽 5、10、15 mg 与安慰剂治疗 72 周对血尿酸(SUA)的影响。结果显示各剂量替尔泊肽均较安慰剂显著降低 SUA,且减重可解释 72.7% 的 SUA 下降。
要点
- 替尔泊肽 5、10、15 mg 治疗 72 周 SUA 分别下降 0.69、0.92、0.95 mg/dL,均高于安慰剂的 0.18 mg/dL。
- 中介分析提示减重可解释 72.7% 的 SUA 下降。
核心结论
- 在肥胖或超重人群中,替尔泊肽与 SUA 水平有意义的降低相关,且似乎主要通过减重实现。
- 原文指出这些发现值得进一步研究替尔泊肽/有意减重对合并肥胖的痛风患者的可能作用。
研究设计与样本
- SURMOUNT-1 随机安慰剂对照试验的事后分析,纳入 2539 例肥胖或超重成人(BMI ≥30 kg/m² 或 ≥27 kg/m² 且至少 1 项体重相关并发症)。
- 受试者随机接受替尔泊肽 5、10 或 15 mg 或安慰剂治疗 72 周,在基线和 72 周内多个时间点测量 SUA,并与安慰剂组比较变化。
- 采用中介分析评估体重变化与 SUA 变化之间的关联。
主要发现
- 替尔泊肽治疗 72 周使体重最多下降 20.9%。
- 第 72 周 SUA 平均变化:替尔泊肽 5 mg 组 -0.69 mg/dL(SE: 0.04),10 mg 组 -0.92 mg/dL(0.04),15 mg 组 -0.95 mg/dL(0.04),安慰剂组 -0.18 mg/dL(0.04),各剂量组与安慰剂比较均 P < .001。
- 与安慰剂相比,SUA 水平随时间显著降低,且不受基线尿酸四分位(P = .610)和基线 BMI 值(P = .362)影响。
- 中介分析提示减重可解释 72.7% 的 SUA 下降。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to test whether tirzepatide, a dual GLP-1RA/GIP agonist, approved for weight management, would be associated with lowered serum uric acid (SUA) levels via its weight reduction properties. METHODS: A post hoc analysis of the SURMOUNT-1 trial, a randomised placebo-controlled trial involving 2539 adults with obesity or overweight (body mass index [BMI] ≥ 30 kg/m2 or ≥27 kg/m2 and at least 1 weight-related complication), randomised to tirzepatide (5, 10, or 15 mg) or placebo for 72 weeks. Tirzepatide treatment over 72 weeks decreased weight by up to 20.9%. SUA was measured at baseline and multiple time points during the 72-week study across the 3 active trial arms, and changes were compared to the placebo arm. The association between weight changes and SUA changes was evaluated by mediation analysis. RESULTS: Treatment with all dose groups of tirzepatide was associated with significant reductions in SUA, compared to placebo. At week 72, the mean change in SUA was -0.69 mg/dL (SE: 0.04), -0.92 mg/dL (0.04), and -0.95 mg/dL (0.04) with 5, 10, and 15 mg of tirzepatide (all P < .001), respectively, and -0.18 mg/dL (0.04) with placebo. SUA levels reduced significantly over time compared to placebo, regardless of baseline uric acid quartiles (P = .610) and baseline BMI values (P = .362). Mediation analysis suggested that weight reduction explained 72.7% of SUA reduction. CONCLUSIONS: In this post hoc analysis, in participants with obesity or overweight, tirzepatide was associated with meaningfully reduced SUA levels, regardless of participants' baseline BMI or SUA levels, and appeared to be so primarily via weight reduction. These findings warrant further investigation into the possible role that tirzepatide/intentional weight loss may play in the treatment of patients with gout living with obesity.
引用
- Sattar N, Scilletta S, Stefanski A, et al. Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial. Ann Rheum Dis. 2025. PMID: 41198460. doi:10.1016/j.ard.2025.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。